PuSH - Publication Server of Helmholtz Zentrum München: Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Lämmer, F.* ; Delbridge, C.* ; Würstle, S.* ; Neff, F.* ; Meyer, B.* ; Schlegel, J.* ; Kessel, K.A. ; Schmid, T.E. ; Schilling, D. ; Combs, S.E.

Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma.

PLoS ONE 14:e0221502 (2019)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Introduction The major stress-inducible heat shock protein 70 (Hsp70) is induced after different stress stimuli. In tumors, elevated intracellular Hsp70 levels were associated on the one hand with radio- and chemotherapy resistance and on the other hand with a favorable outcome for patients. This study was undertaken to investigate cytosolic Hsp70 (cHsp70) as a potential biomarker for progression free (PFS) and overall survival (OS) in patients with primary glioblastomas (GBM). Methods The cHsp70 expression in tumor tissue of 60 patients diagnosed with primary GBM was analyzed by immunohistochemistry. The cHsp70 expression was correlated to the PFS and OS of the patients. Results A high cHsp70 expression was associated with a prolonged PFS (hazard ratio = 0.374, p = 0.001) and OS (hazard ratio = 0.416, p = 0.014) in GBM patients treated according to the standard Stupp protocol with surgery, radiotherapy and temozolomide. Conclusions These data suggest that the intracellular Hsp70 expression might serve as a prognostic marker in patients with primary GBM.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

2.776

1.123